



HAL
open science

Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of nitro-l-arginine methyl ester

Andreea-Teodora Pânzariu, Maria Apotrosoaei, Ioana Mirela Vasincu, Maria Drăgan, Sandra Constantin, Frédéric Buron, Sylvain Routier, Lenuta Profire, Cristina Tuchilus

► **To cite this version:**

Andreea-Teodora Pânzariu, Maria Apotrosoaei, Ioana Mirela Vasincu, Maria Drăgan, Sandra Constantin, et al.. Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of nitro-l-arginine methyl ester. *Chemistry Central Journal*, 2016, 10, pp.6. 10.1186/s13065-016-0151-6 . hal-04451478

HAL Id: hal-04451478

<https://hal.science/hal-04451478>

Submitted on 4 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access



Synthesis and biological evaluation of new 1,3-thiazolidine-4-one derivatives of nitro-L-arginine methyl ester

Andreea-Teodora Pânzariu¹, Maria Apotrosoaei¹, Ioana Mirela Vasincu¹, Maria Drăgan¹, Sandra Constantin¹, Frédéric Buron², Sylvain Routier², Lenuta Profire^{1*} and Cristina Tuchilus³

Abstract

Background: L-Arginine is a semi-essential amino acid with important role in regulation of physiological processes in humans. It serves as precursor for the synthesis of proteins and is also substrate for different enzymes such as nitric oxide synthase. This amino acid acts as free radical scavenger, inhibits the activity of pro-oxidant enzymes and thus acts as an antioxidant and has also bactericidal effect against a broad spectrum of bacteria.

Results: New thiazolidine-4-one derivatives of nitro-L-arginine methyl ester (NO₂-Arg-OME) have been synthesized and biologically evaluated in terms of antioxidant and antibacterial/antifungal activity. The structures of the synthesized compounds were confirmed by ¹H, ¹³C NMR, Mass and IR spectral data. The antioxidant potential was investigated using in vitro methods based on ferric/phosphomolybdenum reducing antioxidant power and DPPH/ABTS radical scavenging assay. The antibacterial effect was investigated against Gram positive (*Staphylococcus aureus* ATCC 25923, *Sarcina lutea* ATCC 9341) and Gram negative (*Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853) bacterial strains. The antifungal activity was also investigated against *Candida* spp. (*Candida albicans* ATCC 10231, *Candida glabrata* ATCC MYA 2950, *Candida parapsilosis* ATCC 22019).

Conclusions: Synthesized compounds showed a good antioxidant activity in comparison with the NO₂-Arg-OME. The antimicrobial results support the selectivity of tested compounds especially on *P. aeruginosa* as bacterial strain and *C. parapsilosis* as fungal strain. The most proper compounds were **6g** (R = 3-OCH₃) and **6h** (R = 2-OCH₃) which showed a high free radical (DPPH, ABTS) scavenging ability and **6j** (R = 2-NO₂) that was the most active on both bacterial and fungal strains and also it showed the highest ABTS radical scavenging ability.

Keywords: Nitro-L-arginine methyl ester, 1,3-Thiazolidine-4-one, Spectral methods, Antioxidant effects, Antibacterial/antifungal activity

Background

L-Arginine is an amino acid with the highest nitrogen content known for its important role in regulation of physiological processes in humans [1]. This amino acid is considered a semi-essential amino acid because normal cells can not only synthesize arginine *de novo* through the ornithine cycle but also uptake extracellular arginine

[2]. It serves as a precursor for the synthesis of proteins and it is also substrate for different enzymes. For example nitric oxide synthase (NOS) converts arginine to nitric oxide (NO) and citrulline. Three isoforms of NOS have been described: endothelial NOS (eNOS), neuronal NOS (nNOS), that are constitutive isoforms (cNOS) and inducible NOS (iNOS) [3]. NO, is an important signal molecule, involved in immune responses, angiogenesis, epithelialization and formation of granulation tissue, vasodilatation of smooth muscle and inhibition of platelets activation/aggregation [4, 5]. The cNOS produce NO in picomolar amounts for short time, being responsible

*Correspondence: lenuta.profire@umfiasi.ro

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy "Grigore T. Popa", 16 University Street, 700115 Iasi, Romania

Full list of author information is available at the end of the article

for regulation of arterial blood pressure, while iNOS produces large amounts of NO through cell activation under inflammatory conditions, appearing to be involved in pathophysiological phenomena [3]. Nitro-L-arginine methyl ester (NO₂-Arg-OMe, L-NAME) is known as selective inhibitor of inducible NOS, which showed antinociceptive effects in mice and reversed thermal hyperalgesia in rats with carrageenan arthritis [6]. It was also reported that L-NAME attenuates the withdrawal from cocaine [7] and prevents the behaviour effects induced by phencyclidin, a dissociative drug [8].

L-Arginine is reported also to act as free radical scavenger, inhibits the activity of pro-oxidant enzymes and thus acts as an antioxidant [9, 10]. This endogenous molecule has also bactericidal effect against a broad spectrum of bacteria, by nitrosation of cysteine and tyrosine residues, which lead to dysfunction of bacterial proteins. This effect could be useful in different conditions as wounds when infection could delay the healing process. The two most common bacteria in wounds are *Pseudomonas aeruginosa* and *Staphylococcus aureus* [11]. In addition, to its role as precursor of NO, L-arginine can be metabolized by arginase to ornithine and urea. Ornithine is an essential precursor for collagen and polyamines synthesis, both required for wound healing processes [12]. Based on all these aspects there has been reported that L-arginine has important roles in Alzheimer disease [13], inflammatory process [14], healing and tissue regeneration [14–16] and also it showed anti-atherosclerotic activity [17, 18].

On other hand the heterocyclic compounds are an integral part in organic chemistry field and constitute a modern research field that is being currently pursued by many research teams [19]. Diversity in the biological response of 1,3-thiazolidine-4-one derivatives had attracted the attention of many researchers for a thorough exploration of their biological potential. These compounds have been reported for their antioxidant [20–22], anti-inflammatory [23], antibacterial/antifungal [24–26], antitumor [27], antidiabetic [28], antihyperlipidemic [29] and antiarthritic [30] effects.

In order to improve the biological effects of L-arginine and, new 1,3-thiazolidine-4-one derivatives have been synthesized. The spectral data (FT-IR, ¹H-NMR,

¹³C-NMR, MS) of each compound were recorded and the compounds were screened for their in vitro antioxidant potential and antibacterial/antifungal activity.


Results and discussion

Chemistry


The synthesis of thiazolidine-4-one compounds derived from L-NO₂-Arg-OMe was performed in two steps and is summarized in Scheme 1 and Table 1. The first step consisted in formation of the 1,3-thiazolidin-4-one cycle via a *one-pot* condensation/cyclization reaction which implies the using of ethyl 3-aminopropionate hydrochloride **1**, different substituted aromatic aldehydes **2a–j** and thioglycolic acid **3** using a similar approach described in our previous work [27]. The product of this reaction was treated with KOH to give compounds **4** in satisfactory to very good overall yields. In the second and last step, the formation of amide bond between acid derivatives **4** and N_ω-nitro-L-arginine methyl ester hydrochloride **5** was carried out using classical conditions in presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBT) to lead to new thiazolidine-4-one derivatives with arginine moiety **6a–j**.

The structure of the compounds was assigned on the basis of spectral data (IR, ¹H-NMR, ¹³C-NMR, MS) which are provided in the Experimental Section. The spectral data for compounds **4a–j** were presented in our previous paper [31].

The analysis of IR spectral data obtained for compounds **6a–j** showed that the NH group corresponding to the amide bond formed was identified between 3305 and 3294 cm⁻¹ in the form of a medium or low intensity bands. The specific anti-symmetric valence vibration of CH₂ group has been reported in the range of 2940–2825 cm⁻¹ and overlaps with specific absorption band of CH group, which is identified in the same range. The C=O group was identified as three absorption bands: the absorption band in the 1760–1670 cm⁻¹ corresponds to ester group (COOCH₃), in the area of 1686–1647 cm⁻¹ was identified the absorption band corresponding to C=O from amide bond and the group C=O from the thiazolidine-4-one moiety appears in the range of



Scheme 1 Synthesis of compounds **6a–j**. Reagents and conditions: **a** DIPEA, toluene, reflux 24–30 h; **b** KOH 1 M, EtOH/THF (1/1), r.t. 8–12 h then HCl 1 M; **c** N_ω-nitro-L-arginine methyl ester hydrochloride (**5**), HOBT, EDC, DCM, r.t. 10–15 h

Table 1 Synthesis of derivatives **4** and **6**

Entry	Comp.	R	4 , Yield ^a (%)	6 , Yield ^a (%)
1	a	H	73	93
2	b	4-CH ₃	55	91
3	c	4-Cl	59	89
4	d	4-F	67	75
5	e	4-Br	78	87
6	f	4-OCH ₃	55	86
7	g	3-OCH ₃	57	78
8	h	2-OCH ₃	64	76
9	i	3-NO ₂	63	50
10	j	2-NO ₂	82	91

^a Yields are indicated in isolated compounds

1647–1610 cm⁻¹. The vibration of C–S bond, specific for thiazolidine-4-one, was identified between 694 and 668 cm⁻¹.

The formation of **6a–j** has also been proved by the NMR data. The thiazolidine-4-one structure was proved by characteristic proton signals. The proton of S–CH–N group appears as doublet in the range of 5.72–6.08 while the two protons from thio-methylene group (S–CH₂) were recorded dispersed; the first resonates between 4.41 and 4.72 ppm, and the second between 3.80 and 4.07 ppm. The amide bond (–NH–CO) was proved by the characteristic proton signal which resonates as singlet in the range 8.48–8.68 ppm.

In the ¹³C-NMR spectra the carbons of thiazolidine-4-one system appear between 64.36 and 62.65 ppm for S–CH–N and between 34.53 and 33.10 ppm for –CH₂–S. The signals for the three CO groups (CO_{thiazolidine}, CO_{amide}, CO_{ester}) appear in the range of 173.24–160.39 ppm, which confirm the success of peptide coupling reaction.

The proton and carbon signals for other characteristics groups were observed according to the expected chemical shift and integral values. The NMR spectral data coupled with mass spectra strong support the proposed structures of each synthesized compounds.

Biological evaluation

Antioxidant activity

The antioxidant activity was evaluated using in vitro tests: DPPH and ABTS radical scavenging,

phosphomolybdenum reducing antioxidant power and ferric reducing antioxidant power assays. For each compound it was calculated effective concentration 50 (EC₅₀) by linear regression. The results were expressed as EC₅₀ value which represents the concentration where half of the substrate is being reduced by the tested compounds.

The DPPH radical scavenging assay

The purple free radical DPPH (2,2-diphenyl-1-(2,4,6-trinitrophenyl)hydrazyl) is a stable compound that can be scavenged through antioxidants by reduction to 2,2-diphenyl-1-(2,4,6-trinitrophenyl)hydrazine, a colorless or yellow product visible at 517 nm [32]. The scavenging activities (%) of thiazolidine-4-one derivatives of nitro-L-arginine methyl ester **6a–j** at different concentrations (0.33, 0.66, 0.99 and 1.32 mg/mL) are presented in Fig. 1. The high values of the scavenging activity indicate a good antiradical effect. The results expressed as EC₅₀ values (mg/mL) are shown in Table 2. Low values of EC₅₀ demonstrate a higher scavenging ability.

It was observed that 1,3-thiazolidine-4-one derivatives of methyl ester of nitro-L-arginine (NO₂-Arg-OMe) showed an improved scavenging ability compared to parent molecule (NO₂-Arg-OMe) and L-arginine, excepting nitro substituted derivatives **6i** and **6j**, which showed comparable antiradical activity. It is also noted that the antiradical activity increases with the concentration, the highest inhibition being recorded at the concentration of 1.32 mg/mL. At this concentration the inhibition rate ranged from 22.62 % for **6d** (R = 4-F) up to 42.61 % for **6h** (R = 2-OCH₃) and 47.63 % for **6a** (R = H).

The scavenging ability depends on the substituent of phenyl ring of thiazolidine-4-one moiety. The most active compound was unsubstituted derivative **6a** (EC₅₀ = 1.7294 ± 0.048), which is 1.6 times more active than NO₂-Arg-OMe (EC₅₀ = 2.7163 ± 0.019). A good influence was showed also by the methoxy substitution in *ortho* and *meta* position, the corresponding compounds **6h** (2-OCH₃, EC₅₀ = 1.8068 ± 0.028) and **6g** (3-OCH₃, EC₅₀ = 1.8868 ± 0.013) being 1.5 times more active than NO₂-Arg-OMe. All tested compounds were less active than vitamin E used as a positive control.

The ABTS radical scavenging assay

The radical of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS⁺) generated by oxidation of ABTS with potassium persulfate is reduced in the presence of hydrogen-donating compounds. The influence of concentration of the antioxidant and duration of reaction on the radical cation absorption inhibition are taken into account for antioxidant activity evaluation [33]. The antioxidants produce a discoloration with a decrease in the absorbance measured at 734 nm [34].




Table 2 The DPPH scavenging ability (EC_{50} mg/mL) of derivatives **6a–j**

Compound	EC_{50} (mg/mL)	Compound	EC_{50} (mg/mL)
6a	1.7294 ± 0.048	6g	1.8869 ± 0.013
6b	2.5980 ± 0.013	6h	1.8068 ± 0.028
6c	2.5354 ± 0.021	6i	2.7992 ± 0.012
6d	2.6176 ± 0.012	6j	2.8034 ± 0.014
6e	2.2430 ± 0.032	NO₂-Arg-OMe	2.7163 ± 0.019
6f	2.4751 ± 0.015	L-Arg	2.8157 ± 0.017
Vitamin E	0.0018 ± 0.008		

Data are mean ± SD (n = 3, p < 0.05)

The ABTS radical scavenging ability (%) of **6a–j** at different concentrations (0.1, 0.15, 0.25, 0.5 mg/mL) are presented in Fig. 2. The high values of scavenging activity indicate a good antiradical effect. The results expressed as EC_{50} values (mg/mL) are presented in Table 3. Low values of EC_{50} indicate a higher effectiveness in ABTS scavenging ability.

The data showed that ABTS⁺ is inhibited in a higher rate than DPPH radical, all derivatives being more active than parent compound. This means that the chemical modulation made on the NO₂-Arg-OMe scaffold improves the radical scavenging activity. The radical scavenging ability increases with the concentration, the highest inhibition being recorded at the concentration of 0.5 mg/mL (Fig. 2). At this concentration the inhibition rate ranged from 48.15 % for **6e** (R = 4-Br) up to 89.26 % for **6h** (R = 3-NO₂) and 91.55 % for **6j** (R = 2-NO₂), the inhibition percentage being approximately 2 times higher than the DPPH inhibition percentage.

The activity is depending on the substitution of phenyl ring of thiazolidine-4-one scaffold (Table 3). The most active compounds were **6j**, **6g** and **6h** that have nitro in *ortho* position and methoxy in *ortho* and *para* position respectively. These compounds are 35 times (**6j**, $EC_{50} = 0.0525 \pm 0.015$), 22 times (**6g**, $EC_{50} = 0.0827 \pm 0.017$) and 20 times (**6h**, $EC_{50} = 0.0918 \pm 0.032$) more active than NO₂-Arg-OMe ($EC_{50} = 1.8487 \pm 0.026$). A very good activity was showed also by the compounds **6c** and **6d** that have chloro and fluoro in *para* position of phenyl ring. They are 10 times (**6c**, $EC_{50} = 0.1885 \pm 0.014$) and 11 times (**6d**, $EC_{50} = 0.1720 \pm 0.018$) respectively more active than NO₂-Arg-OMe. It is also noted that all tested compounds are more active than L-arginine but less active than vitamin E used as a positive control.

Phosphomolybdenum reducing antioxidant power (PRAP) assay

The total antioxidant activity was determined by the formation of phosphomolybdenum blue complex by the reduction of Mo⁶⁺ to Mo⁵⁺ under the action of electron donating compounds. The maximum absorption of the complex was recorded at 695 nm and the reducing antioxidant effectiveness is correlated with high absorbance values [35]. The graphical representation of the absorbance values at different concentrations (0.18, 0.36, 0.54 and 0.72 mg/mL) is shown in Fig. 3. As we expected, the absorbance of **6a–j** increases with the concentration, the highest absorbance/activity being recorded at the concentration of 0.72 mg/mL.

The data support the positive influence of thiazolidine-4-one moiety for increase the antioxidant effect




Table 3 The ABTS scavenging ability (EC_{50} mg/mL) of derivatives 6a–j

Compound	EC_{50} (mg/mL)	Compound	EC_{50} (mg/mL)
6a	0.4699 ± 0.013	6g	0.0827 ± 0.017
6b	0.4967 ± 0.015	6h	0.0918 ± 0.032
6c	0.1885 ± 0.014	6i	0.9434 ± 0.018
6d	0.1720 ± 0.018	6j	0.0525 ± 0.015
6e	0.5954 ± 0.029	NO₂-Arg-OMe	1.8487 ± 0.026
6f	0.4182 ± 0.012	L-Arg	2.0574 ± 0.011
Vitamin E	0.0075 ± 0.008		

Data are mean ± SD (n = 3, p < 0.05)

of NO₂-Arg-OMe, the corresponding compound **6a** ($EC_{50} = 1.6235 \pm 0.015$) being 1.6 times more active than NO₂-Arg-OMe ($EC_{50} = 2.6169 \pm 0.032$) (Table 4). Regarding the influence of radicals which substitute the phenyl ring from thiazolidine-4-one it was observed that the most favorable influence was exerted by the substitution in *para* with Br, the corresponding compound **6e**, ($EC_{50} = 0.6405 \pm 0.012$) being 4 times more active than the NO₂-Arg-OMe. Although the activity of the all tested compounds is more intense than L-arginine, they are less active than vitamin E used as a positive control.

Ferric reducing antioxidant power (FRAP) assay

The ferric reducing antioxidant power assay is a sensitive method based on the reduction of ferricyanide to ferrocyanide in the presence of antioxidants with electron-donating abilities. Ferrocyanide is quantified as Perl's Prussian Blue, complex which has a maximum absorption band at 700 nm [36]. The absorbance values of our

compounds at different concentrations (0.56, 1.13, 2.27, 4.54 mg/mL) are shown in Fig. 4 and the EC_{50} values are presented in Table 5.

The derivatization of NO₂-Arg-OMe through an introduction of thiazolidine-4-one moiety via amide chain has a great influence on antioxidant potential, all the tested compounds being more active than parent molecule (NO₂-Arg-OMe) and L-arginine. The most active compounds were **6e** ($EC_{50} = 2.5781 \pm 0.012$) and **6c** ($EC_{50} = 3.2742 \pm 0.019$) which contain bromo and chloro in *para* position of phenyl ring. These compounds were 4.5 times and 3.4 times respectively more active than NO₂-Arg-OMe ($EC_{50} = 11.0778 \pm 0.016$). A good influence was produced also by substitution in *meta* position with methoxy and nitro, the corresponding compounds being 2.5 times (**6i**, $EC_{50} = 4.5202 \pm 0.014$) and 2.4 times (**6g**, $EC_{50} = 4.6474 \pm 0.018$) more active than NO₂-Arg-OMe. All tested compounds were less active than vitamin E used as a positive control.

Antibacterial/antifungal assays

The antibacterial and antifungal activity of our derivatives was evaluated using the agar disc diffusion method and broth micro-dilution method.

The agar disc diffusion method

The data presented in Table 6 show that tested compounds are active on both bacterial and fungal strains, their effect being more intense or comparable with parent molecule (NO₂-Arg-OMe). The main characteristic of the tested compounds is their activity on *P. aeruginosa* ATCC 27853, a Gram-negative bacterial strain frequently




Table 4 The phosphomolybdenum reducing antioxidant power (EC₅₀ mg/mL) of **6a–j** derivatives

Compound	EC ₅₀ (mg/mL)	Compound	EC ₅₀ (mg/mL)
6a	1.6235 ± 0.015	6g	2.7332 ± 0.037
6b	2.0679 ± 0.018	6h	3.5186 ± 0.018
6c	2.0734 ± 0.022	6i	2.1837 ± 0.024
6d	2.1706 ± 0.014	6j	2.4610 ± 0.019
6e	0.6405 ± 0.012	NO₂-Arg-OMe	2.6169 ± 0.032
6f	2.3827 ± 0.013	L-Arg	2.7534 ± 0.006
Vitamin E	0.0385 ± 0.001		

Data are mean ± SD (n = 3, p < 0.05)

found in wounds. This effect is important because Gram-negative bacteria are more resistant than Gram-positive ones to the treatment due to lipopolysaccharide-rich

outer membrane which significantly reduces the intracellular penetration of antibiotics [36, 37]. It is noted that in similar experimental conditions, ampicillin and chloramphenicol, used as standard drugs, were inactive on *P. aeruginosa* ATCC 27853, the data being in agreement with other experimental studies [38, 39]. The most proper compound seems to be **6j** which has nitro in *ortho* position of phenyl ring. This compound was the most active against *S. aureus*, *Sarcina lutea* and *P. aeruginosa* strains in comparison with NO₂-Arg-OMe (**5**).

Regarding the antifungal activity the data support the positive influence of *nitro* substitution of phenyl ring, the corresponding compounds being more active than NO₂-Arg-OMe, especially on *Candida albicans* (**6i**, R = 3-NO₂, **6j**, R = 2-NO₂) and *Candida glabrata* (**6i**, R = 3-NO₂). On *C. glabrata* a good activity was showed




Table 5 The ferric reducing antioxidant power (EC₅₀, mg/mL) of 6a–j

Compound	EC ₅₀ (mg/mL)	Compound	EC ₅₀ (mg/mL)
6a	7.1876 ± 0.038	6g	4.6474 ± 0.018
6b	9.0695 ± 0.015	6h	7.9317 ± 0.023
6c	3.2742 ± 0.019	6i	4.5202 ± 0.014
6d	8.9671 ± 0.023	6j	7.3504 ± 0.011
6e	2.5781 ± 0.012	NO₂-Arg-OMe	11.0778 ± 0.016
6f	6.1302 ± 0.032	L-Arg	10.9321 ± 0.015
Vitamin E	0.0109 ± 0.003		

Data are mean ± SD (n = 3, p < 0.05)

also by **6d** (R = 4-F). Referring to *Candida parapsilosis* strain it is noted that all tested compounds were more active than parent compound (NO₂-Arg-OMe, **5**) and nystatin.

The broth micro-dilution method

After the antimicrobial activity was proved, the next step was to establish the minimal inhibitory concentration (MIC) and the minimal bactericidal/fungicidal concentration (MBC/MFC) using the broth micro-dilution method.

The antibacterial activity of **6j** is supported by the MIC and MBC values (Table 7); this compound having smaller values than NO₂-Arg-OMe for *S. aureus* and *Escherichia*

coli. A good activity against these bacterial strains was also showed by the **6c**, which contains chloro in *para* position of phenyl ring of thiazolidine-4-one moiety. The data support also the antibacterial effect of **6i** and **6f** against *P. aeruginosa*, their MIC and MBC values being smaller than NO₂-Arg-OMe.

Although the results obtained using agar disc diffusion method support that some of tested compounds are more active than positive control (ampicillin and chloramphenicol), this observation has not been proved by the MIC and MBC values. All tested compounds were less active ampicillin and chloramphenicol on tested bacterial strains, except *P. aeruginosa* ATCC 27853.

The results obtained for antifungal activity (Table 8) support the selectivity of the almost tested compounds, included the parent compound (NO₂-Arg-OMe), on *C. parapsilosis* strain. For this strain the MIC values of almost tested compounds were comparable with nystatin while the MFC values were even lower than it. The data support also the activity of **6i** on *C. albicans* in comparison with NO₂-Arg-OMe.

Experimental section

General methods

All chemicals used for the synthesis of the desired compounds were obtained from Sigma Aldrich Company and Fluka Company and were used as received without additional purification. The melting points were measured

Table 6 Antibacterial/antifungal inhibition area (mm) of 6a–j derivatives

Sample	Diameter of inhibition area ^a (mm)						
	Bacterial strains				Yeasts strains		
	SA	SL	EC	PA	CA	CG	CP
6a	15.2 ± 0.12	19.3 ± 0.15	10.1 ± 0.06	13.1 ± 0.24	11.8 ± 0.35	15.2 ± 0.28	23.0 ± 0.19
6b	14.1 ± 0.08	20.1 ± 0.13	15.1 ± 0.23	11.2 ± 0.41	12.9 ± 0.06	15.2 ± 0.98	24.1 ± 0.65
6c	15.2 ± 0.16	18.1 ± 0.78	11.2 ± 0.63	11.9 ± 0.09	9.9 ± 0.62	13.8 ± 0.07	21.2 ± 0.33
6d	15.3 ± 0.68	18.2 ± 0.55	10.2 ± 0.37	–	13.2 ± 0.21	16.4 ± 0.78	24.2 ± 0.35
6e	12.1 ± 0.09	20.1 ± 0.43	10.1 ± 0.32	11.1 ± 0.19	12.1 ± 0.58	15.9 ± 0.55	25.3 ± 0.28
6f	15.2 ± 0.52	20.1 ± 0.26	12.2 ± 1.05	10.2 ± 0.36	12.1 ± 0.18	15.5 ± 0.48	25.1 ± 0.37
6g	13.1 ± 0.15	20.1 ± 0.72	–	10.1 ± 0.09	12.1 ± 0.28	15.9 ± 1.07	25.2 ± 0.39
6h	14.1 ± 0.09	20.3 ± 0.43	11.1 ± 0.30	10.2 ± 0.15	12.1 ± 0.86	13.8 ± 0.57	23.1 ± 0.22
6i	12.3 ± 0.08	21.1 ± 0.13	10.1 ± 0.23	12.2 ± 0.41	15.4 ± 0.06	16.4 ± 0.98	20.1 ± 0.65
6j	16.3 ± 0.34	21.2 ± 0.87	10.2 ± 0.51	13.1 ± 0.82	15.2 ± 0.74	15.2 ± 0.32	23.1 ± 0.47
5	14.9 ± 0.16	19.9 ± 0.12	11.9 ± 0.06	11.8 ± 0.19	13.8 ± 0.15	15.9 ± 0.17	19.9 ± 0.09
A	20.1 ± 0.57	21.2 ± 1.16	15.2 ± 0.67	–	–	–	–
C	16.3 ± 0.28	30.4 ± 0.35	20.1 ± 0.16	–	–	–	–
N	–	–	–	–	19.4 ± 0.51	19.5 ± 0.72	12.4 ± 0.42

SA = *Staphylococcus aureus* ATCC 25923; SL = *Sarcina lutea* ATCC 9341; EC = *Escherichia coli* ATCC 25922; PA = *Pseudomonas aeruginosa* ATCC 27853; CA = *Candida albicans* ATCC 10231; CG = *Candida glabrata* ATCC MYA 2950; CP = *Candida parapsilosis* ATCC 22019; **5** = NO₂-Arg-OMe; **A** = ampicillin; **C** = chloramphenicol; **N** = nystatin. **5** = L-NO₂-Arg-OMe

^a Mean values (n = 3) ± standard deviation

Table 7 Antibacterial effect expressed as MIC and MBC values (mg/mL) of 6a–j

Sample	<i>S. aureus</i> ATCC 25923		<i>S. lutea</i> ATCC 9341		<i>E. coli</i> ATCC 25922		<i>P. aeruginosa</i> ATCC 27853	
	MIC ^a	MBC ^a	MIC ^a	MBC ^a	MIC ^a	MBC ^a	MIC ^a	MBC ^a
6a	2.5	2.5	0.01	0.01	1.25	1.25	2.5	2.5
6b	1.25	2.5	0.03	1.25	2.5	10	2.5	10
6c	0.01	0.01	0.01	0.03	0.03	0.03	5	5
6d	2.5	2.5	0.01	0.03	1.25	5	1.25	1.25
6e	0.01	0.3	0.01	0.01	10	5	5	5
6f	0.07	2.5	0.03	0.15	0.03	0.15	0.03	1.25
6g	2.5	2.5	0.03	1.25	1.25	1.25	2.5	10
6h	2.5	2.5	0.01	0.01	1.25	5	2.5	2.5
6i	0.3	0.3	0.01	0.01	0.1	0.1	0.03	0.6
6j	0.07	0.07	0.01	0.01	0.03	0.03	1.25	1.25
5	2.5	2.5	0.01	0.01	1.25	1.25	1.25	1.25
A	0.0002	0.0005	0.0002	0.0005	0.008	0.016	nt	nt
C	0.008	0.016	0.003	0.006	0.008	0.016	nt	nt

5 = L-NO₂-Arg-OMe, A = ampicillin; C = chloramphenicol; nt = no tested

^a Mean values (n = 3) ± standard deviation

Table 8 Antifungal effect expressed as MIC and MFC values (mg/mL) of 6a–j

Sample	<i>C. albicans</i> ATCC 10231		<i>C. glabrata</i> ATCC MYA 2950		<i>C. parapsilosis</i> ATCC 22019	
	MIC ^a	MFC ^a	MIC ^a	MFC ^a	MIC ^a	MFC ^a
6a	0.6	1.25	1.25	1.25	0.003	0.003
6b	0.6	1.25	2.5	10	0.003	0.003
6c	0.6	0.6	10	10	0.003	0.003
6d	0.3	1.25	0.6	2.5	0.003	0.003
6e	10	10	10	10	5	5
6f	0.6	0.6	2.5	5	0.003	0.003
6g	0.3	1.25	1.25	2.5	0.003	0.003
6h	0.3	5	10	10	0.003	0.003
6i	0.03	10	10	10	10	10
6j	0.3	1.25	1.25	1.25	0.003	0.003
5	1.25	1.25	0.6	2.5	0.003	0.003
N	0.004	0.008	0.004	0.008	0.004	0.008

5 = L-NO₂-Arg-OMe, N = nystatin

^a Mean values (n = 3) ± standard deviation

using a Buchi Melting Point B-540 apparatus and they are uncorrected. The FT-IR spectra were recorded on Horizon MBTM FT-IR, over a 500–4000 cm⁻¹ range, after 16 scans at a resolution of 4 cm⁻¹. The spectra processing was carried out with the Horizon MBTM FTIR Software. The ¹H-NMR (400 MHz) and ¹³C-NMR (101 MHz) spectra were obtained on a Bruker Avance 400 MHz spectrometer using tetramethylsilane as internal standard and deuterated chloroform as solvent (CDCl₃). The chemical shifts were shown in δ values (ppm). The mass

spectra were registered using a Bruker MaXis Ultra-High Resolution Quadrupole Time-of-Flight Mass Spectrometer. The progress of the reaction was monitored on TLC, using pre-coated Kieselgel 60 F254 plates (Merck, Whitehouse Station, NJ, USA) and the compounds were visualized using UV light. E-factor and material efficiency (ME) have been selected to evaluate the greenness of the synthetic procedures. E-factor is a very useful metric tool that is defined as E-Factor = mass of wastes/mass of product. The E-factor can be used to calculate the

material efficiency of the process according to the equation: $ME = 1/E\text{-factor} + 1$ [40].

The antioxidant potential was investigated using in vitro methods based on ferric/phosphomolybdenum reducing antioxidant power and DPPH/ABTS radical scavenging assay. The antibacterial activity was evaluated using Gram-positive (*S. aureus* ATCC 25923, *S. lutea* ATCC 9341) and Gram-negative (*E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853) bacterial strains. The antifungal activity was evaluated using *C. albicans* ATCC 10231, *C. glabrata* ATCC MYA 2950 and *C. parapsilosis* ATCC 22019. All strains were obtained from the Culture Collection of the Department of Microbiology, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania. As positive controls were used ampicillin, a beta-lactam drug, and chloramphenicol which belongs amphenicoles class for antibacterial activity and nystatin for antifungal activity.

General procedure for synthesis

of N^2 -[(2-aryl-4-oxo-1,3-thiazolidin-3-yl)

propionyl]-nitro-L-arginine methyl ester (6a-j)

3-(2-Phenyl-4-oxo-1,3-thiazolidin-3-yl)propionic acid derivatives, **4a-j** (5 mmol) were dissolved in 25 mL freshly distilled DCM, on ice bath at 0–5 °C and under inert atmosphere of nitrogen [41]. To the cold solution it was added EDCl.HCl (5.5 mmol, 1.1 equiv.), HOBT (5.5 mmol, 1.1 equiv.) and NO₂-L-Arg-OMe.HCl (5.5 mmol, 1.1 equiv.). The mixture was stirred for 10–14 h at room temperature. The reaction monitoring was carried out by Thin Layer Chromatography (TLC) using as mobile phase DCM: methanol (MeOH) = 9.5:0.5 (v/v) and the spot visualization was done under UV light at 254 nm. After the completion of the reaction, the mixture was washed successively with 1 M HCl, saturated solution of sodium bicarbonate and saturated brine solution. The organic layer, was dried over anhydrous MgSO₄, filtered and concentrated to dryness. Purification of compounds was carried out by column separation on silica gel (DCM/MeOH, 9.5/0.5). The appropriate fractions of thiazolidine-4-one derivatives was collected and then evaporated to dryness to give the corresponding final derivatives.

N^2 -[(2-Phenyl-4-oxo-1,3-thiazolidin-3-yl)

propionyl]-nitro-L-arginine methyl ester (6a)

White crystals, mp 102 °C, yield: 93 %, IR (Zn/Se crystal, cm⁻¹): 3294 (–NH); 2963, 783 (=CH_{phenyl}); 2869, 1250, 725 (–CH₂–); 1736 (COOCH₃); 1647 (CONH); 1628 (C=O_{thiazolidine-4-one}); 1535 (–C=C_{phenyl}); 1350, 1026 (–C–N–); 698 (C–S); ¹H-NMR (δ ppm): 8.51 (s, 1H, NH–CO), 8.03 (m, 1H, NH), 7.56–7.47 (m, 2H, NH), 7.38–7.29 (m, 5H, Ar–H), 5.77 (d, J = 55.7 Hz, 1H, –N–CH–S), 4.61 (s, 1H, CH₂–S), 3.89 (s, 1H, CH₂–S), 3.78 (s, 3H, CH₃

ester), 3.73 (s, 1H, CH–COOCH₃), 3.69 (s, 1H, N–CH₂), 3.39–3.30 (m, 2H, CH₂ arg), 3.23–3.01 (m, 1H, N–CH₂), 2.62–2.34 (m, 2H, CH₂–CO), 1.94–1.54 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 172.32, 171.28, 162.09 (3C, CO), 159.64 (C_{guanid}), 139.15, 129.72, 129.42, 127.45, 127.33, 117.60 (6C, C_{Ar}), 64.36 (S–CH–N–), 52.99 (CH₂), 48.47 (CH), 39.75 (–CH₂N–), 33.99 (–CH₂S–), 33.33 (CH₂), 32.98 (–CH₂CO), 24.29 (CH₂), 20.57 (CH₃); HRMS (EI-MS): *m/z* calculated for C₁₉H₂₆N₆O₆S [M + H]⁺ 467.1707; found is 467.1705; Green chemistry metrics: E-factor 22.513, ME 0.042.

N^2 -[(2-(4-Methylphenyl)-4-oxo-1,3-thiazolidin-3-yl)

propionyl]-nitro-L-arginine methyl ester (6b)

Light yellow crystals, mp 90 °C, yield: 91 %, IR (Zn/Se crystal, cm⁻¹): 3305 (–NH); 2951, 771 (=C–H_{phenyl}); 2928, 1257, 721 (–CH₂–); 1724 (COOCH₃); 1678 (CONH); 1628 (C=O_{thiazolidine-4-one}); 1597 (–C=C_{phenyl}); 1362, 1026 (–C–N–); 694 (C–S); ¹H-NMR (δ ppm): 8.68 (s, 1H, NH–CO), 8.31 (m, 1H, NH), 7.80 (s, 2H, NH), 7.26–7.34 (m, 4H, Ar–H), 5.82 (d, J = 18.8 Hz, 1H, –N–CH–S), 4.57 (s, 1H, CH₂–S), 3.92 (dd, J = 13.6, 6.8 Hz, 1H, CH₂–S), 3.81 (s, 3H, CH₃ ester), 3.78 (s, 1H, CH–COOCH₃), 3.71 (s, 1H, N–CH₂), 3.53–3.31 (m, 2H, CH₂ arg), 3.24–3.05 (m, 1H, N–CH₂), 2.62 (dd, J = 18.0, 7.9 Hz, 2H, CH₂–CO), 2.41 (s, 3H, CH₃), 2.02–1.62 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 172.47, 171.28, 170.76 (3C, CO), 159.40 (C_{guanid}), 138.24, 134.57 (2C, C_{Ar}), 128.95 (2C, CH_{Ar}), 123.31 (2C, CH_{Ar}), 63.25 (S–CH–N), 50.34 (CH), 40.73 (CH₂), 39.58 (–CH₂N–), 33.45 (–CH₂S–), 32.84 (–CH₂CO), 29.14 (CH₂), 24.29 (CH₂), 26.37, 21.34 (2C, CH₃); HRMS (EI-MS): *m/z* calculated for C₂₀H₂₈N₆O₆S [M + H]⁺ 481.1862; found 481.1864; Green chemistry metrics: E-factor 16.891, ME 0.056.

N^2 -[(2-(4-Chlorophenyl)-4-oxo-1,3-thiazolidin-3-yl)

propionyl]-nitro-L-arginine methyl ester (6c)

Light yellow crystals, mp 146 °C, yield: 89 %, IR (Zn/Se crystal, cm⁻¹): 3302 (–NH); 2951, 783 (=C–H_{phenyl}); 2928, 1257, 725 (–CH₂–); 1736 (COOCH₃); 1651 (–CONH); 1628 (C=O_{thiazolidine-4-one}); 1597 (–C=C_{phenyl}); 1342, 1014 (–C–N–); 764 (C–Cl); 683 (C–S); ¹H-NMR (δ ppm): 8.68 (s, 1H, NH–CO), 8.26 (m, 1H, NH), 7.75 (s, 2H, NH), 7.32 (d, J = 8.2 Hz, 2H, Ar–H), 7.28–7.23 (d, 2H, Ar–H), 5.75 (d, J = 26.3 Hz, 1H, –N–CH–S), 4.52 (s, 1H, CH₂–S), 3.79 (dd, J = 15.8, 8.6 Hz, 1H, CH–COOCH₃), 3.71 (s, 1H, CH₂–S), 3.68 (s, 3H, CH₃ ester), 3.64 (s, 1H, N–CH₂), 3.31 (d, J = 44.9 Hz, 2H, CH₂ arg), 3.11–2.94 (m, 1H, N–CH₂), 2.65–2.29 (m, 2H, CH₂–CO), 1.90–1.56 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 173.24, 171.99, 169.52 (3C, CO), 160.48 (C_{guanid}), 138.42, 135.80 (C_{Ar}), 130.05 (2C, CH_{Ar}), 129.37 (2C, CH_{Ar}), 63.94 (S–CH–N), 53.38 (CH₂), 51.34 (CH), 41.42 (CH₂), 39.10

($-\underline{\text{C}}\underline{\text{H}}_2\text{N}-$), 34.19 ($-\underline{\text{C}}\underline{\text{H}}_2\text{S}-$), 31.53 ($-\underline{\text{C}}\underline{\text{H}}_2\text{CO}$), 29.57 ($\underline{\text{C}}\underline{\text{H}}_3$); 26.45 ($\underline{\text{C}}\underline{\text{H}}_3$); HRMS (EI-MS): m/z calculated for $\text{C}_{19}\text{H}_{25}\text{ClN}_6\text{O}_6\text{S}$ [$\text{M} + \text{H}$] $^+$ 501.1317; found 501.1310; Green chemistry metrics: E-factor 2.361, ME 0.297.

N^2 -[(2-(4-Fluorophenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6d)

Light yellow crystals, mp 85 °C, yield: 75 %; IR (Zn/Se crystal, cm^{-1}): 3302 ($-\text{NH}$); 2951, 787 ($=\text{C}-\text{H}_{\text{phenyl}}$); 2933, 1257, 725 ($-\text{CH}_2-$); 1736 (COOCH_3); 1651 ($-\text{CONH}$); 1647 ($\text{C}=\text{O}_{\text{thiazolidine-4-one}}$); 1601 ($-\text{C}=\text{C}_{\text{phenyl}}$); 1342, 1011 ($-\text{C}-\text{N}-$); 1153 ($\text{C}-\text{F}$); 687 ($\text{C}-\text{S}$); $^1\text{H-NMR}$ (δ ppm): 8.63 (s, 1H, $\text{NH}-\text{CO}$), 8.24 (m, 1H, NH), 7.61 (s, 2H, NH), 7.37 (dd, $J = 13.7, 5.7$ Hz, 2H, Ar-H), 7.11 (t, $J = 8.4$ Hz, 2H, Ar-H), 5.80 (d, $J = 50.0$ Hz, 1H, $-\text{N}-\underline{\text{C}}\underline{\text{H}}-\text{S}$), 4.72–4.41 (m, 1H, CH_2-S), 3.94–3.85 (m, 1H, $\underline{\text{C}}\underline{\text{H}}-\text{COOCH}_3$), 3.80 (s, 1H, CH_2-S), 3.75 (s, 3H, $\underline{\text{C}}\underline{\text{H}}_3$ ester), 3.71 (s, 1H, $\text{N}-\text{CH}_2$), 3.52–3.27 (m, 2H, CH_2 arg), 3.20–3.00 (m, 1H, $\text{N}-\text{CH}_2$), 2.68–2.27 (m, 2H, CH_2-CO), 1.84–1.59 (m, 4H, 2CH_2 arg); $^{13}\text{C-NMR}$ (δ ppm): 171.80, 170.76, 162.34 (3C, $\underline{\text{C}}\underline{\text{O}}$), 158.81 (C_{guanid}), 161.58, 135.57 (2C, C_{Ar}), 128.32 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 115.61 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 62.65 ($\text{S}-\underline{\text{C}}\underline{\text{H}}-\text{N}$), 52.15 ($\underline{\text{C}}\underline{\text{H}}$), 39.93 ($-\text{CH}_2\text{N}-$), 38.85 ($\underline{\text{C}}\underline{\text{H}}_2$), 33.10 ($-\text{CH}_2\text{S}-$), 32.16 ($-\text{CH}_2\text{CO}$), 29.24 ($\underline{\text{C}}\underline{\text{H}}_2$), 28.67 ($\underline{\text{C}}\underline{\text{H}}_2$), 21.34 ($\underline{\text{C}}\underline{\text{H}}_3$); HRMS (EI-MS): m/z calculated for $\text{C}_{19}\text{H}_{25}\text{FN}_6\text{O}_6\text{S}$ [$\text{M} + \text{H}$] $^+$ 485.1614; found 485.1613; Green chemistry metrics: E-factor 1.122, ME 0.471.

N^2 -[(2-(4-Bromophenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6e)

Light yellow crystals, mp 109 °C, yield: 87 %; IR (Zn/Se crystal, cm^{-1}): 3294 ($-\text{NH}$); 2954, 776 ($=\text{C}-\text{H}_{\text{phenyl}}$); 1736 (COOCH_3); 1647 ($-\text{CONH}$); 1628 ($\text{C}=\text{O}_{\text{thiazolidine-4-one}}$); 1601 ($-\text{C}=\text{C}_{\text{phenyl}}$); 1342, 1007 ($-\text{C}-\text{N}-$); 1246, 725 ($-\text{CH}_2-$); 687 ($\text{C}-\text{S}$); 668 ($\text{C}-\text{Br}$); $^1\text{H-NMR}$ (δ ppm): 8.68 (s, 1H, $\text{NH}-\text{CO}$), 8.19 (m, 1H, NH), 7.76 (s, 2H, NH), 7.54 (d, $J = 7.6$ Hz, 2H, Ar-H), 7.36–7.16 (m, 2H, Ar-H), 5.79 (d, $J = 29.5$ Hz, 1H, $-\text{N}-\underline{\text{C}}\underline{\text{H}}-\text{S}$), 4.59 (s, 1H, CH_2-S), 3.86 (dd, $J = 17.6, 10.2$ Hz, 1H, CH_2-S), 3.78 (s, 3H, $\underline{\text{C}}\underline{\text{H}}_3$ ester), 3.77 (s, 1H, $\underline{\text{C}}\underline{\text{H}}-\text{COOCH}_3$), 3.72 (d, $J = 15.6$ Hz, 1H, $\text{N}-\text{CH}_2$), 3.37 (d, $J = 45.7$ Hz, 2H, CH_2 arg), 3.09 (dd, $J = 31.1, 10.2$ Hz, 1H, $\text{N}-\text{CH}_2$), 2.74–2.51 (m, 1H, CH_2-CO), 2.43–2.37 (m, 1H, CH_2-CO), 1.82 (d, $J = 78.0$ Hz, 4H, 2CH_2 arg); $^{13}\text{C-NMR}$ (δ ppm): 172.47, 170.18, 161.28 (3C, $\underline{\text{C}}\underline{\text{O}}$), 159.40 (C_{guanid}), 138.24, 132.34 (2C, C_{Ar}), 128.95 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 123.31 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 63.25 ($\text{S}-\underline{\text{C}}\underline{\text{H}}-\text{N}$), 52.71 ($\underline{\text{C}}\underline{\text{H}}$), 40.73 ($\underline{\text{C}}\underline{\text{H}}_2$), 39.58 ($-\text{CH}_2\text{N}-$), 33.45 ($-\text{CH}_2\text{S}-$), 32.04 ($-\text{CH}_2\text{CO}$), 29.14 ($\underline{\text{C}}\underline{\text{H}}_2$), 28.67 ($\underline{\text{C}}\underline{\text{H}}_2$), 25.44 ($\underline{\text{C}}\underline{\text{H}}_3$); HRMS (EI-MS): m/z calculated for $\text{C}_{19}\text{H}_{25}\text{BrN}_6\text{O}_6\text{S}$ [$\text{M} + \text{H}$] $^+$ 545.0811; found 545.0812; Green chemistry metrics: E-factor 1.874, ME 0.352.

N^2 -[(2-(4-Methoxyphenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6f)

Light yellow crystals, mp 95 °C, yield: 86 %; IR (Zn/Se crystal, cm^{-1}): 3298 ($-\text{NH}$); 3001, 783 ($=\text{C}-\text{H}_{\text{phenyl}}$); 1740 (COOCH_3); 1651 ($-\text{CONH}$); 1628 ($\text{C}=\text{O}_{\text{thiazolidine-4-one}}$); 1609 ($-\text{C}=\text{C}_{\text{phenyl}}$); 1346, 1111 ($-\text{C}-\text{N}-$); 1246, 725 ($-\text{CH}_2-$); 1153 ($-\text{OCH}_3$); 687 ($\text{C}-\text{S}$); $^1\text{H-NMR}$ (δ ppm): 8.60 (s, 1H, $\text{NH}-\text{CO}$), 8.21 (m, 1H, NH), 7.63 (s, 2H, NH), 7.38–7.18 (m, 2H, Ar-H), 6.91 (d, $J = 8.6$ Hz, 2H, Ar-H), 5.73 (d, $J = 42.3$ Hz, 1H, $-\text{N}-\underline{\text{C}}\underline{\text{H}}-\text{S}$), 4.65–4.53 (m, 1H, CH_2-S), 3.90–3.84 (m, 1H, CH_2-S), 3.82 (s, 3H, $\underline{\text{C}}\underline{\text{H}}_3$ ester), 3.76 (d, $J = 3.3$ Hz, 3H, OCH_3), 3.71 (s, 1H, $\underline{\text{C}}\underline{\text{H}}-\text{COOCH}_3$), 3.52–3.27 (m, 2H, CH_2 arg), 3.22–3.01 (m, 1H, $\text{N}-\text{CH}_2$), 2.61–2.48 (m, 1H, $\text{N}-\text{CH}_2$), 2.42–2.27 (m, 1H, CH_2-CO), 1.95–1.85 (m, 1H, CH_2-CO), 1.77–1.54 (m, 4H, 2CH_2 arg); $^{13}\text{C-NMR}$ (δ ppm): 172.40, 171.99, 160.63 (3C, $\underline{\text{C}}\underline{\text{O}}$), 159.62 (C_{guanid}), 130.67, 130.11 (2C, C_{Ar}), 128.96 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 114.70 (2C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 63.80 ($\text{S}-\underline{\text{C}}\underline{\text{H}}-\text{N}$), 55.71 ($\underline{\text{C}}\underline{\text{H}}$), 52.92 (OCH_3), 40.46 ($\underline{\text{C}}\underline{\text{H}}_2$), 39.56 ($-\text{CH}_2\text{N}-$), 33.94 ($-\text{CH}_2\text{S}-$), 32.92 ($\underline{\text{C}}\underline{\text{H}}_2$), 29.51 ($-\text{CH}_2\text{CO}$), 23.68 ($\underline{\text{C}}\underline{\text{H}}_2$), 21.45 ($\underline{\text{C}}\underline{\text{H}}_3$); HRMS (EI-MS): m/z calculated for $\text{C}_{20}\text{H}_{28}\text{N}_6\text{O}_7\text{S}$ [$\text{M} + \text{H}$] $^+$ 497.1813; found 497.1813; Green chemistry metrics: E-factor 1.506, ME 0.403.

N^2 -[(2-(3-Methoxyphenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6g)

Light pink crystals, mp 103 °C, yield: 78 %; IR (Zn/Se crystal, cm^{-1}): 3298 ($-\text{NH}$); 3001, 771 ($=\text{C}-\text{H}_{\text{phenyl}}$); 2951, 1254, 725 ($-\text{CH}_2-$); 1740 (COOCH_3); 1651 ($-\text{CONH}$); 1647 ($\text{C}=\text{O}_{\text{thiazolidine-4-one}}$); 1601 ($-\text{C}=\text{C}_{\text{phenyl}}$); 1338, 1041 ($-\text{C}-\text{N}-$); 1149 ($-\text{OCH}_3$); 694 ($\text{C}-\text{S}$); $^1\text{H-NMR}$ (δ ppm): 8.52 (s, 1H, $\text{NH}-\text{CO}$), 8.09 (m, 1H, NH), 7.52–7.47 (m, 2H, NH), 7.32 (t, $J = 7.9$ Hz, 1H, Ar-H), 6.97–6.85 (m, 2H, Ar-H), 6.74 (dd, $J = 31.2, 7.7$ Hz, 1H, Ar-H), 5.72 (d, $J = 63.5, 5.7$ Hz, 1H, $-\text{N}-\underline{\text{C}}\underline{\text{H}}-\text{S}$), 4.68–4.54 (m, 1H, CH_2-S), 3.94–3.85 (m, 1H, CH_2-S), 3.82 (s, 3H, $\underline{\text{C}}\underline{\text{H}}_3$ ester), 3.79–3.78 (d, $J = 3.5$ Hz, 3H, OCH_3), 3.72 (s, 1H, $\underline{\text{C}}\underline{\text{H}}-\text{COOCH}_3$), 3.57–3.29 (m, 2H, CH_2 arg), 3.25–3.05 (m, 1H, $\text{N}-\text{CH}_2$), 2.55 (dt, $J = 7.6, 6.9$ Hz, 1H, $\text{N}-\text{CH}_2$), 2.45–2.32 (m, 1H, CH_2-CO), 1.91 (dd, $J = 8.5, 4.0$ Hz, 1H, CH_2-CO), 1.77–1.55 (m, 4H, 2CH_2 arg); $^{13}\text{C-NMR}$ (δ ppm): 172.37, 170.65, 160.39 (3C, $\underline{\text{C}}\underline{\text{O}}$), 159.66 (C_{guanid}), 140.76, 130.52 (2C, C_{Ar}), 119.47, 114.98, 114.75, 113.11 (4C, $\underline{\text{C}}\underline{\text{H}}_{\text{Ar}}$), 64.07 ($\text{S}-\underline{\text{C}}\underline{\text{H}}-\text{N}$), 55.56 ($\underline{\text{C}}\underline{\text{H}}$), 53.01 (OCH_3), 40.57 ($\underline{\text{C}}\underline{\text{H}}_2$), 39.79 ($-\text{CH}_2\text{N}-$), 34.05 ($-\text{CH}_2\text{S}-$), 31.94 ($-\text{CH}_2\text{CO}$), 29.65, 24.27 (2CH_2), 21.34 ($\underline{\text{C}}\underline{\text{H}}_3$); HRMS (EI-MS): m/z calculated for $\text{C}_{20}\text{H}_{28}\text{N}_6\text{O}_7\text{S}$ [$\text{M} + \text{H}$] $^+$ 497.1813; found 497.1812; Green chemistry metrics: E-factor 3.767, ME 0.213.

***N*²-[(2-(2-Methoxyphenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6h)**

Light yellow crystals, mp 115 °C, yield: 76 %; IR (Zn/Se crystal, cm⁻¹): 3298 (–NH); 3078, 771 (=C–H_{phenyl}); 2947, 1242, 725 (–CH₂–); 1736 (COOCH₃); 1647 (–CONH); 1628 (C=O_{thiazolidine-4-one}); 1597 (–C=C–_{phenyl}); 1350, 1049 (–C–N–); 1153 (–OCH₃); 683 (C–S); ¹H-NMR (δ ppm): 8.48 (s, 1H, NH–CO), 7.94 (m, 1H, NH), 7.50 (s, 2H, NH), 7.34 (t, J = 7.9 Hz, 1H, Ar–H), 7.15 (dd, J = 13.1, 4.3 Hz, 1H, Ar–H), 7.05–6.92 (m, 1H, Ar–H), 6.84–6.74 (m, 1H, Ar–H), 6.08 (d, J = 37.2 Hz, 1H, –N–CH–S), 4.69–4.51 (m, 1H, CH₂–S), 3.94 (t, J = 7.2 Hz, 1H, CH₂–S), 3.90–3.86 (s, 3H, CH₃ ester), 3.78 (d, J = 3.1 Hz, 3H, OCH₃), 3.66–3.56 (m, 1H, CH–COOCH₃), 3.40 (dd, J = 69.6, 5.1 Hz, 2H, CH₂ arg), 3.11 (ddd, J = 11.9, 9.6, 6.4 Hz, 1H, N–CH₂), 2.72–2.53 (m, 1H, N–CH₂), 2.46 (dt, J = 15.2, 6.2 Hz, 1H, CH₂–CO), 2.01–1.86 (m, 1H, CH₂–CO), 1.78–1.48 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 172.98, 171.33, 164.37 (3C, CO), 159.94 (C_{guanid}), 157.47, 130.82 (2C, C_{Ar}), 127.38 (CH_{Ar}), 121.55 (2C, CH_{Ar}), 111.78 (CH_{Ar}), 63.95 (S–CH–N), 56.21 (CH), 53.30 (OCH₃), 40.81 (CH₂), 39.19 (–CH₂N–), 34.53 (–CH₂S–), 33.10 (CH₂), 31.43 (–CH₂CO), 24.91 (CH₂), 22.17 (CH₃); RMS (EI-MS): *m/z* calculated for C₂₀H₂₈N₆O₇S [M + H]⁺ 497.1813; found 497.1814; Green chemistry metrics: E-factor 2.079, ME 0.325.

***N*²-[(2-(3-Nitrophenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6i)**

Light yellow crystals, mp 100 °C, yield: 50 %; IR (Zn/Se crystal, cm⁻¹): 3302 (–NH); 3090, 783 (=C–H_{phenyl}); 2951, 1257, 729 (–CH₂–); 1736 (COOCH₃); 1651 (–CONH); 1632 (C=O_{thiazolidine-4-one}); 1601 (–C=C–_{phenyl}); 1528, 1350 (NO₂); 1219, 1095 (–C–N–); 683 (C–S); ¹H-NMR (δ ppm): 8.58 (s, 1H, NH–CO), 8.21 (d, J = 4.3 Hz, 2H, Ar–H), 8.03 (m, 1H, NH), 7.77–7.67 (m, 1H, Ar–H), 7.61 (t, J = 8.0 Hz, 1H, Ar–H), 7.49–7.34 (m, 2H, NH), 5.93 (d, J = 34.7 Hz, 1H, –N–CH–S), 4.60 (s, 1H, CH₂–S), 3.98–3.83 (m, 1H, CH₂–S), 3.79 (s, 3H, CH₃ ester), 3.76 (d, J = 4.6 Hz, 1H, CH–COOCH₃), 3.59–3.39 (m, 2H, CH₂ arg), 3.36–3.22 (m, 1H, N–CH₂), 3.24–3.00 (m, 1H, N–CH₂), 2.74–2.35 (m, 2H, CH₂–CO), 1.84–1.55 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 173.24, 171.67, 168.34 (3C, CO), 160.14 (C_{guanid}), 149.41, 142.55 (2C, C_{Ar}), 135.30, 133.92, 131.10, 129.30 (4C, CH_{Ar}), 63.58 (S–CH–N), 53.54 (CH), 41.32 (CH₂), 39.41 (CH₂N–), 34.37 (–CH₂S–), 33.48 (CH₂), 31.94 (–CH₂CO), 24.27 (CH₂), 22.37 (CH₃); HRMS (EI-MS): *m/z* calculated for C₁₉H₂₅N₇O₈S [M + H]⁺ 512.1558; found 512.1554; Green chemistry metrics: E-factor 3.687, ME 0.2134.

***N*²-[(2-(2-Nitrophenyl)-4-oxo-1,3-thiazolidin-3-yl)propionyl]-nitro-L-arginine methyl ester (6j)**

Yellow crystals, mp 95 °C, yield: 98 %; IR (Zn/Se crystal, cm⁻¹): 3302 (–NH); 2983, 767 (=C–H_{phenyl}); 2954, 1257, 725 (–CH₂–); 1736 (COOCH₃); 1659 (–CONH); 1628 (C=O_{thiazolidine-4-one}); 1606 (–C=C–_{phenyl}); 1524, 1342 (NO₂); 1215, 1115 (–C–N–); 687 (C–S); ¹H-NMR (δ ppm): 8.58 (s, 1H, NH–CO), 8.21 (m, 1H, NH), 8.15–8.06 (m, 1H, Ar–H), 7.72 (dd, J = 11.5, 3.8 Hz, 1H, Ar–H), 7.52 (dd, J = 11.4, 4.0 Hz, 1H, Ar–H), 7.35–7.28 (m, 1H, Ar–H), 7.20–7.14 (m, 2H, NH), 6.30 (d, J = 23.8 Hz, 1H, –N–CH–S), 4.57 (d, J = 7.2 Hz, 1H, CH₂–S), 4.07–3.94 (m, 1H, CH₂–S), 3.77 (d, J = 13.6 Hz, 3H, CH₃ ester), 3.71–3.66 (m, 1H, CH–COOCH₃), 3.61 (dd, J = 15.7, 2.8 Hz, 2H, CH₂ arg), 3.49–3.28 (m, 1H, N–CH₂), 3.17–3.02 (m, 1H, N–CH₂), 2.71–2.47 (m, 1H, CH₂–CO), 2.02–1.85 (m, 1H, CH₂–CO), 1.77–1.61 (m, 4H, 2CH₂ arg); ¹³C-NMR (δ ppm): 172.01, 170.56, 162.34 (3C, CO), 159.04 (C_{guanid}), 146.93, 136.09 (2C, C_{Ar}), 134.38, 129.13, 125.70, 116.24 (4C, CH_{Ar}), 63.95 (S–CH–N), 58.72 (CH), 40.21 (CH₂), 39.33 (–CH₂N–), 33.64 (–CH₂S–), 31.27 (CH₂), 31.94 (–CH₂CO), 29.55 (CH₂), 24.26 (CH₃); HRMS (EI-MS): *m/z* calculated for C₁₉H₂₅N₇O₈S [M + H]⁺ 512.1558; found 512.1559; Green chemistry metrics: E-factor 1.218, ME 0.452.

Biological evaluation**Antioxidant activity****DPPH radical scavenging assay**

The radical scavenging activity of the tested compounds towards 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical was measured as described in literature [32] with minor modifications. The samples were dissolved in DMSO in order to form the stock solutions with the concentration of 20 mg/mL. From the stock solutions there were taken different volumes (50, 100, 150, 200 μL) and completed up to 200 μL with methanol, then it was added 2800 μL of 0.1 mM DPPH methanol solution. The resulting mixture was kept in the dark for 60 min after which the absorbance was read at 517 nm against methanol, used as a blank solution. The final concentration of sample in the test tube was 0.33, 0.66, 0.99 and 1.32 mg/mL respectively. The DPPH radical-inhibiting capacity (radical scavenging ability) was calculated using the following formula:

$$\text{Inhibition (scavenging activity)\%} = [(A_C - A_S)/A_C] \times 100 \quad (1)$$

where A_C = absorbance of the DPPH solution, A_S = absorbance of the sample. Vitamin E (α-tocopherol) was used as positive control and as references were used NO₂-Arg-OMe and L-arginine, all three being processed

in a similar manner with the samples. All determinations were performed in triplicate.

ABTS radical scavenging assay

The generation of radical cation ABTS⁺ was carried out by treating the aqueous solution of 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (7 mM) with ammonium persulfate (2.45 mM). The resulting mixture was kept in the dark for 16 h to promote the formation of ABTS⁺, as described in [33, 34]. The ABTS⁺ radical cation solution was diluted with ethanol to obtain an absorbance value of 0.7 ± 0.02 at 734 nm. Different sample volumes (10, 15, 25, 50 μ L) from a stock solution of 20 mg/mL in DMSO were mixed with DMSO to 50 μ L and then 1950 μ L of ABTS⁺ solution were added. The final concentration of sample in the test tube was 0.1, 0.15, 0.25 and 0.50 mg/mL respectively. After 6 min the absorbance was measured at 734 nm against a blank (ethanol) and the radical scavenging capacity was calculated according to the following equation:

$$\text{Scavenging activity \%} = [(A_C - A_S)/A_C] \times 100 \quad (2)$$

where A_C = absorbance of ABTS⁺ alcoholic solution; A_S = absorbance of the samples, read at 6 min after the addition of the ABTS⁺ solution. Vitamin E (α -tocopherol) was used as positive control and as references were used NO₂-Arg-OMe and L-arginine, all three being processed in a similar manner with the samples. All determinations were performed in triplicate.

Phosphomolybdenum reducing antioxidant power (PRAP) assay

The total antioxidant activity of tested compounds was evaluated using the phosphomolybdenum method according to the procedure described in the literature [35] with minor modifications. For each compound was prepared a stock solution with the concentration of 20 mg/mL in DMSO, from which there were used different volumes (20, 40, 60, 80 μ L) and completed with DMSO up to 200 μ L. Over these samples it was added 2 mL of the reagent solution (0.6 M sulfuric acid, 28 mM disodium hydrogen phosphate, and 4 mM ammonium molybdate). The samples were incubated at 95 °C for 90 min at drying stove (oven). The final concentration of sample in the test tube was 0.18, 0.36, 0.54 and 0.72 mg/mL respectively. After cooling to room temperature, the absorbance was read at 695 nm against a blank (200 mL DMSO + 2 mL reagent). Vitamin E (α -tocopherol) was used as positive control and as references were used NO₂-Arg-OMe and L-arginine, all three being processed in a similar manner with the samples. All determinations were performed in triplicate.

Ferric reducing antioxidant power (FRAP) assay

The ferric reducing antioxidant power of the compounds was quantified by the method described by [36] with slight modifications. The compounds were tested at different concentrations (20, 10, 5, 2.5 mg/mL). To 0.5 mL of samples of each concentration it was added 0.5 mL of 0.2 M phosphate buffer pH 6.6. The reaction was then initiated by the addition of 0.5 mL of potassium ferricyanide 1 % w/v, after which the samples are incubated at 50 °C (oven) for 20 min and the completion of the reaction takes place by addition of 0.5 mL trichloroacetic acid 10 % w/v. 1 mL from the resulting solution of each sample was diluted with 1 mL double distilled deionised water and finally 0.2 mL of ferric chloride 0.1 % w/v was added. The final concentration of sample in the test tube was 4.5454, 2.2727, 1.1360, 0.5681 mg/mL respectively. The mixture was left at room temperature for 10 min and then the absorbance was measured at 700 nm against a blank solution prepared similar to the sample, which contain 0.5 mL DMSO instead 0.5 mL sample. Vitamin E (α -tocopherol) was used as positive control and as references were used NO₂-Arg-OMe and L-arginine, all three being processed in a similar manner with the samples. All determinations were performed in triplicate.

Antibacterial/antifungal assays

Agar disc diffusion method Antibacterial and antifungal activity of the 6a–j derivatives expressed as diameter of inhibition area was evaluated by the standard disk diffusion assay according to described protocols [42]. Prior to use, the strains (bacteria and yeasts) were diluted in sterile 0.9 % NaCl until the turbidity was equivalent to McFarland standard no. 0.5 (106 CFU/mL). The suspensions were further diluted 1:10 in Mueller–Hinton agar for bacteria and Sabouraud agar for fungi and then spread on sterile Petri plates (25 mL/Petri plate). Sterile stainless steel cylinders (5 mm internal diameter; 10 mm height) were applied on the agar surface in Petri plates. In each cylinder 200 μ L of sample solutions in DMSO (20 mg/mL) was added. As positive control there were used commercial available discs containing ampicillin (25 mcg/disc), chloramphenicol (30 mcg/disc) and nystatin (100 mcg/disc). DMSO was used as a negative control. The plates were incubated at 37 °C for 24 h (bacteria) and at 24 °C for 48 h (fungi). The diameters of inhibition area developed after the incubation were measured.

The broth micro-dilution method The minimum inhibitory concentration (MIC) and the minimum bactericidal/fungicidal concentration (MBC/MFC) against bacteria and fungi respectively were determined by the two-fold dilution method, with minor modification [38].

The active cultures of the bacteria and fungi were prepared by transferring the loopful of cells from the stock culture to the conical flasks containing Mueller–Hinton broth for bacteria or Sabouraud broth for fungi. The cultures were incubated at 37 °C for 24 h (bacteria) and at 24 °C for 48 h (fungi) and then were diluted with fresh media to obtain an optical density value of 106 CFU/mL. Different dilutions of the 6a–j derivatives made in the Mueller–Hinton broth (bacteria) and in Sabouraud broth (fungi) were prepared in a 96-well microplate by the twofold dilution method in the concentration range of 10, 5, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.039, 0.0195, 0.009 and 0.0048 mg/mL. Then 10 µL of each strain (106 CFU/mL) was inoculated onto the microplates. The plates were incubated again at 37 °C for 24 h. The lowest concentrations of the tested compounds which did not show any visual growth of the test strain, were determined as the MICs, which were expressed in mg/mL. For the determination of MBCs and MFCs, the MIC and the next higher concentrations of the sample were selected, spread on the agar plates, and incubated at 37 °C for 24 h. The concentration of the tested compounds, which did not show any growth of the microorganism on the agar plates, was determined as the MBC/MFC and expressed in mg/mL. Each determination was performed in triplicate.

Conclusions

The present work is centered on the synthesis and biological evaluation of new thiazolidine-4-ones derived from the methyl ester of nitro-L-arginine. The structure of the compounds was proven using spectral methods (IR, ¹H-NMR, ¹³C-NMR, MS). The antioxidant activity was quantified using four in vitro tests: DPPH/ABTS scavenging assays and ferric/phosphomolybdenum reducing antioxidant power assays. The *methoxy*-substituted derivatives, **6h** (R = 2-OCH₃) and **6g** (3-OCH₃), showed a high free radical scavenging ability, both for DPPH and ABTS radicals. A good influence was exerted also by the *nitro* and *bromo* substitution. The 2-*nitro*-derivative, **6j**, showed the best ABTS scavenging ability while the 4-*bromo*-derivative, **6e**, presented the best ferric and phosphomolybdenum reducing antioxidant power. The compound **6j** also showed a good antibacterial and antifungal activity. It was the most active on *S. aureus*, *S. lutea* and *P. aeruginosa* and *Candida* spp. respectively. The encouraging preliminary results support the antioxidant and antibacterial/antifungal potential of the synthesized compounds and their possible applications in several diseases mediated by reactive oxygen species (ROS) and susceptible to infections such as wound healing from burns.

Authors' contributions

A-TP, FB, SR and LP designed research; A-TP, MA, IMV, MD and SC performed research; A-TP, FB, SR and LP analyzed the spectral data; A-TP, CT and LP analyzed the biological data; A-TP, LP, FB and SR wrote the paper. All authors read and approved the final manuscript.

Author details

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy "Grigore T. Popa", 16 University Street, 700115 Iasi, Romania. ² Institut de Chimie Organique et Analytique – ICOA UMR7311, Pôle de chimie, Rue de Chartres, 45100 Orléans, France. ³ Department of Microbiology, Faculty of Pharmacy, University of Medicine and Pharmacy "Grigore T. Popa", 16 University Street, 700115 Iasi, Romania.

Acknowledgements

The research was funded by POSDRU Grant No. 159/1.5/S/136893 grant with title "Parteneriat strategic pentru creşterea calităţii cercetării ştiinţifice din universităţile medicale prin acordarea de burse doctorale şi post-doctorale–DocMed.Net_2.0" (partially) and by a Grant of the Romanian National Authority for Scientific Research, CNCS—UEFISCDI, Project Number PNII-ID-PCE-2011-3-0906.

Competing interests

The authors declare that they have no competing interests.

Received: 11 November 2015 Accepted: 21 January 2016

Published online: 04 February 2016

References

- Gad MZ (2010) Anti-aging effects of L-arginine (review). *J Adv Res* 1:169–177
- Wu G, Jaeger LA, Bazer FW, Rhoads JM (2004) Arginine deficiency in preterm infants: biochemical mechanisms and nutritional implications. *J Nutr Biochem* 15:332–451
- Gogoi M, Datey A, Wilson K, Chakravorty D (2016) Dual role of arginine metabolism in establishing pathogenesis. *Curr Opin Microbiol* 2:43–48
- Kirk SJ, Hurson M, Regan MC, Holt DR, Wasserkrug HL, Barbul A (1993) Arginine stimulates wound healing and immune function in elderly human beings. *Surgery* 114:155–159
- Nigris F, Lerman LO, Ignarro SW, Sica G, Lerman A, Palinski W, Ignarro LJ, Napoli C (2003) Beneficial effects of antioxidants and L-arginine on oxidation-sensitive gene expression and endothelial NO synthase activity at sites of disturbed shear stress. *Proc Natl Acad Sci USA* 100:1420–1425
- Rocha J, Peixoto M, Jancar S, Cunha F, Ribeiro R, Rocha F (2002) Dual effect of nitric oxide in articular inflammatory pain in zymosan-induced arthritis in rats. *Br J Pharmacol* 136:588–596
- Klamer D, Palsson E, Wass C, Archer T, Engel JA, Svensson L (2005) Antagonism of the nitric oxide synthase inhibitor, L-NAME, of the effects of phenylcyclidine on latent inhibition in taste aversion conditioning. *Behav Brain Res* 161(1):60–68
- Rawls SM, Rodriguez T, Baron DA, Raffa RB (2006) A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. *Brain Res* 1:82–87
- Wallner S, Hermetter A, Mayer B, Wascher TC (2001) The alpha-amino group of L-arginine mediates its antioxidant effects. *Eur J Clin Invest* 31:98–102
- Tripathi P, Misra MK (2009) Therapeutic role of L-arginine on free radical scavenging system in ischemic heart diseases. *Indian J Biochem Biophys* 46:498–502
- Kim JO, Noh J-K, Thapa RK, Hasan N, Choi M, Kim JH, Lee J-H, Ku SK, Yoo J-W (2015) Nitric oxide-releasing chitosan film for enhanced antibacterial and in vivo wound-healing efficacy. *Int J Biol Macromol* 79:217–225
- Debats IJBG, Wolfs TGAM, Gotoh T, Cleutjens JPM, Peutz-Kootstra CJ, Van der Hulst R (2009) Role of arginine in superficial wound healing. *Nitric Oxide* 15:147–156

13. Jing Y, Horky L, Friedlich AL, Ying S, Rogers JT, Xudong H (2009) L-Arginine and Alzheimer's disease. *Int J Clin Exp Pathol* 2:211–238
14. Pekarova M, Lojek A (2015) The crucial role of L-arginine in macrophage activation: what you need to know about it. *Life Sci* 137:44–48
15. Witte MB, Barbul A (2003) Arginine physiology and its implications for wound healing. *Wound Repair Regen* 11:419–423
16. Evans RW, Fernstrom JD, Thompson J, Morris SM, Kuller LH (2004) Biochemical responses of healthy subjects during dietary supplementation with L-arginine. *J Nutr Biochem* 15:534–539
17. Das UN (2015) Nutritional factors in the prevention and management of coronary artery disease and heart failure. *Nutrition* 31(2):283–291
18. Panza JA, Casino PR, Badar DM, Quyyumi AA (1993) Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. *Circulation* 87:1475–1481
19. Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A, Saraf SK (2014) 4-Thiazolidinones: the advances continue. *Eur J Med Chem* 72:52–77
20. Isloor A, Sunil D, Shetty P, Malladi S, Pai K, Maliyakki N (2013) Synthesis, characterization, anticancer, antioxidant activity of some new thiazolidin-4-ones in MCF-7 cells. *Med Chem Res* 22:758–767
21. Šarkanj B, Molnar M, Čačić M, Gille L (2013) 4-Methyl-7-hydroxycoumarin antifungal and antioxidant activity enhancement by substitution with thiosemicarbazide and thiazolidinone moieties. *Food Chem* 139:488–495
22. Mei-Hsiu S, Fang-Ying K (2004) Syntheses and evaluation of antioxidant activity of sydnonyl substituted thiazolidinone and thiazoline derivatives. *Bioorg Med Chem* 12:4633–4643
23. Apostolidis I, Liaras K, Geronikaki A, Hadjipavlou-Litina D, Gavalas A, Soković M (2013) Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-yl-imino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents. *Bioorg Med Chem* 21:532–539
24. Ramachandran R, Rani M, Kabilan S (2009) Design, synthesis and biological evaluation of novel 2-[(2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-ylidene)hydrazono]-1,3-thiazolidin-4-ones as a new class of antimicrobial agents. *Bioorg Med Chem Lett* 19:2819–2823
25. Liesen AP, de Aquino TM, Carvalho CS, Lima VT, de Araújo JM, de Lima JG, de Faria AR, de Melo EJ, Alves AJ, Alves EW, Alves AQ, Góes AJ (2010) Synthesis and evaluation of anti-toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles. *Eur J Med Chem* 45:3685–3689
26. Aquino TM, Liesen AP, Da Silva RE, Lima VT, Carvalho CS, Faria AR, Araujo M, Lima JG, Alves AJ, Melo EJ, Goes AJ (2008) Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidine acetic acids. *Bioorg Med Chem* 16:446–456
27. Revelant G, Huber-Villaume S, Dunand S, Kirsch G, Schohn H, Hesse S (2015) Synthesis and biological evaluation of novel 2-heteroaryl-imino-1,3-thiazolidin-4-ones as potential anti-tumor agents. *Eur J Med Chem* 94:102–112
28. Ottanà R, Maccari R, Giglio M, Del Corso A, Cappiello M, Mura U, Cosconati S, Marinelli L, Novellino E, Sartini S, La Motta C, Da Settimo F (2011) Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. *Eur J Med Chem* 46:2797–2806
29. Khanna V, Kanji S, Nampurath GK, Chamallamudi MR, Mathew SP, Zachariah RT (2008) Assessment of hypolipidaemic activity of three thiazolidin-4-ones in mice given high-fat diet and fructose. *Chem Biol Interact* 171:363–368
30. Verma RP, Hansch C (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. *Bioo. Med Chem* 15:2223–2268
31. Apotrosoaei M, Vasincu I, Drăgan O, Buron F, Routier S, Profire L (2014) Design, synthesis and the biological evaluation of 1,3-thiazolidine-4-ones based on 4-amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one scaffold. *Molecules* 19:13824–13847
32. Schaich KM, Tian X, Xie J (2015) Hurdles and pitfalls in measuring antioxidant efficacy: a critical evaluation of ABTS, DPPH, and ORAC assays. *J Funct Foods* 14:111–125
33. Sadiq A, Mahmood F, Ullah F, Ayaz M, Ahmad S, Haq FU, Khan G, Jan MS (2015) Synthesis, anticholinesterase and antioxidant potentials of ketoesters derivatives of succinimides: a possible role in the management of Alzheimer's. *Chem Cent J* 9:31
34. Tabassum S, Kumara THS, Jasinski JP, Millikan SP, Yathirajan HS, Ganapathy PSS, Sowmya HBV, More SS, Nagendrappa G, Kaur M, Jose L (2014) Synthesis, crystal structure, ABTS radical-scavenging activity, antimicrobial and docking studies of some novel quinoline derivatives. *J Mol Struct* 1070:10–20
35. Cacic M, Molnar M, Sarkanj B, Has-Schon E, Rajkovic V (2010) Synthesis and antioxidant activity of some new coumarinyl-1,3-thiazolidine-4-ones. *Molecules* 15:6795–6809
36. Lungu Apetrei C, Tuchilus C, Aprotosoaei AC (2011) Chemical, antioxidant and antimicrobial investigations of *Pinus cembra* L. bark and needles. *Molecules* 16:7773–7788
37. Kubo I, Fujita K, Kubo A, Nihei K, Ogura T (2004) Antibacterial activity of coriander volatile compounds against *Salmonella choleraesuis*. *J Agric Food Chem* 52:3329–3332
38. Clinical and Laboratory Standards Institute (2015) Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. M100 S25. Clinical and laboratory standards institute, Wayne, PA
39. Andrews JM (2001) Determination of minimum inhibitory concentrations. *J Antimicrob Chemother* 48(S1):5–16
40. Protti S, Dondi D, Fagnoni M, Albini A (2009) Assessing photochemistry as a green synthetic method. Carbon-carbon bond forming reactions. *Green Chem* 11:239–249
41. Sambarkar PB, Patil AC (2012) Synthesis of amides from acid and amine using coupling reagents. *J Curr Pharm Res* 10:22–24
42. Brown DFJ, Blowers R (1978) Disc methods of sensitivity testing and other semiquantitative methods. In: Reeves DS, Phillips I, Williams JD, Wise R (eds) *Laboratory methods in antimicrobial chemotherapy*. Churchill Livingstone Edinburgh, UK, pp 8–23

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
